Whitehawk Therapeutics, Inc. (WHWK) — Cash Flow-to-Debt Ratio
Whitehawk Therapeutics, Inc. (WHWK) has a Cash Flow-to-Debt Ratio of -1.56x as of September 2025, meaning its operating cash flow of $-15.38 Million could theoretically repay -2% of its total liabilities ($9.85 Million) in one year. See Whitehawk Therapeutics, Inc. (WHWK) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Whitehawk Therapeutics, Inc. Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Whitehawk Therapeutics, Inc. across 6 annual periods. Also explore Whitehawk Therapeutics, Inc. (WHWK) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Whitehawk Therapeutics, Inc. (2019–2024)
Year-by-year debt coverage analysis for Whitehawk Therapeutics, Inc.. For market capitalisation and broader financial context, see Whitehawk Therapeutics, Inc. (WHWK) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.34x | $-59.55 Million | $17.84 Million | ▼ -52.3% |
| 2023 | -2.19x | $-59.66 Million | $27.23 Million | ▼ -14.1% |
| 2022 | -1.92x | $-49.64 Million | $25.86 Million | ▼ -84.1% |
| 2021 | -1.04x | $-22.42 Million | $21.50 Million | ▼ -156.6% |
| 2020 | -0.41x | $-12.70 Million | $31.26 Million | ▼ -38.0% |
| 2019 | -0.29x | $-7.58 Million | $25.75 Million | — |